

## Dermavant is committed to fostering unprecedented change and unparalleled impact in immuno-dermatology.

We're doing this by thinking differently, pushing the boundaries of science and partnering with providers in new ways—all with one goal: transforming the lives of millions of patients with skin diseases.

## Dermavant at a glance

- A biopharmaceutical company
- Founded September 2015
- A subsidiary of Roivant Sciences
- U.S. operations in Long Beach, CA, Raleigh-Durham, NC, and Dallas, TX

## About Dermavant

### A Passion for Science and a Commitment to Dermatology

Dermavant Sciences, a subsidiary of Roivant Sciences, is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. Dermavant's focus is to develop therapies that have the potential to address high unmet medical needs while driving greater efficiency in research and clinical development.

The company's medical dermatology pipeline includes commercialized, late-stage and early-development product candidates that target specific unmet needs in two of the largest growing immuno-dermatology markets — plaque psoriasis and atopic dermatitis — as well as other immunological and inflammatory diseases.

Dermavant launched its first product, VTAMA<sup>®</sup> (tapinarof) cream, 1%, for the topical treatment of plaque psoriasis in adults in 2022. Dermavant is also developing VTAMA cream for the treatment of atopic dermatitis in adults and children as young as 2 years old. Atopic dermatitis, the most common type of eczema, affects more than 9.6 million children and 16.5 million adults in the United States.

## Management team

### Todd Zavodnick

Chief Executive Officer

### Philip M. Brown, MD, JD

Chief Medical Officer

### Chris Chapman

Chief Commercial Officer

### David Rubenstein, MD, PhD

Chief Scientific Officer

### Michael Swartzburg

Chief Financial Officer

### Christopher Van Tuyl, JD

Chief Legal Officer

### IMPORTANT SAFETY INFORMATION

**Indication:** VTAMA<sup>®</sup> (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults. **Adverse Events:** The most common adverse reactions (incidence  $\geq$  1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088.

# Dermavant has VTAMA cream and candidates in development addressing: Adult Plaque Psoriasis, Atopic Dermatitis, and Immunological and Inflammatory Diseases

PRODUCT CANDIDATE	POTENTIAL INDICATION	STAGE OF DEVELOPMENT					
		Preclinical	Phase 1	Phase 2	Phase 3	FDA Review	Commercial
<b>VTAMA® (DMVT-505)</b> A topical aryl hydrocarbon receptor (AhR) agonist	<b>Adult Plaque Psoriasis</b>	[Progress bar spanning Preclinical, Phase 1, Phase 2, Phase 3, FDA Review, and Commercial]					
<b>Tapinarof (DMVT-505)</b> A topical aryl hydrocarbon receptor (AhR) agonist	<b>Atopic Dermatitis</b>	[Progress bar spanning Preclinical, Phase 1, Phase 2, Phase 3, FDA Review, and Commercial]					
<b>DMVT-506</b> Next-generation aryl hydrocarbon receptor (AhR) agonist under development for multiple routes of administration	<b>Immunological and Inflammatory Diseases</b>	[Progress bar spanning Preclinical, Phase 1, Phase 2, Phase 3, FDA Review, and Commercial]					

# DERMAVANT. INNOVATING. PIONEERING. TRANSFORMING.



1-8-DERMAVANT (1-833-762-8268)

**Company locations:**

**Long Beach, California Office**  
 Dermavant Sciences, Inc.  
 3780 Kilroy Airport Way, Suite 250  
 Long Beach, CA 90806

**Dallas, Texas Office**  
 Dermavant Sciences, Inc.  
 2102 E. State Hwy. 114, Suite 217  
 Southlake, Texas 76092

**Raleigh-Durham, North Carolina Office**  
 Dermavant Sciences, Inc.  
 3300 Paramount Parkway, Suite 150  
 Morrisville, NC 27560

**Basel, Switzerland Office**  
 Dermavant Sciences GmbH  
 Viaduktstrasse 8  
 4051 Basel



© 2023 Dermavant Sciences, Inc.  
 All rights reserved. All trademarks are the property of Dermavant Sciences, GmbH.